Related Experiment Videos
[Sarcoma of the endometrial stroma]
G A Melilli1, G Di Vagno, A Di Gesù
1Istituto di Clinica Ostetrica e Ginecologica II, Università degli Studi, Bari.
Minerva Ginecologica
|March 9, 1999
Summary
Endometrial stromal sarcoma (ESS) is rare. Low-grade ESS has a high survival rate with surgery alone, while high-grade ESS requires chemotherapy for better outcomes.
Area of Science:
- Gynecologic Oncology
- Pathology
- Surgical Oncology
Context:
- Endometrial stromal sarcoma (ESS) is a rare uterine malignancy.
- Understanding risk factors and treatment efficacy is crucial for patient outcomes.
- Limited data exists on the long-term prognosis of ESS subtypes.
Purpose:
- To evaluate the key risk factors associated with endometrial stromal sarcoma.
- To assess the therapeutic efficacy of current treatment modalities for ESS.
- To analyze the epidemiological, histopathological, and clinical characteristics of ESS patients.
Summary:
- This study reviewed 5 cases of ESS over 9 years, staged using FIGO criteria.
- Low-grade ESS (2 cases) underwent surgery with good outcomes.
- High-grade ESS (3 cases) received surgery and chemotherapy, with survival ranging from 14 to 30 months.
Impact:
- Identifies prognostic differences between low-grade and high-grade ESS.
- Highlights the importance of multimodal therapy for advanced-stage ESS.
- Provides insights into the survival rates and potential outcomes for ESS patients.